<DOC>
	<DOC>NCT01467778</DOC>
	<brief_summary>This is a Phase I study to assess the safety of three formulations of the dermal implant ELAPR.</brief_summary>
	<brief_title>Safety Study of Three Formulations of the Dermal Implant ELAPR</brief_title>
	<detailed_description>A Phase I study to assess the safety of three formulations of the dermal implant ELAPR in healthy subjects.</detailed_description>
	<mesh_term>Skin Diseases</mesh_term>
	<criteria>Good general health status Clinically significant abnormalities of haematology or biochemistry testing Bleeding diathesis, anticoagulant drugs,thrombocytopenia or clinically significant prolonged APTT or PT Chronic use of aspirin, other nonsteroidal antiinflammatory drugs or other antiplatelet agents History of keloid formation Systemic corticosteroids within last 12 weeks Diabetes or metabolic disorders Any serious medical condition which in the opinion of the investigator would have a strong possibility of requiring systemic corticosteroid medication Pregnancy/lactation A history of anaphylaxis or allergic reactions including any known hypersensitivity to Hyaluronic acid or lidocaine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>skin</keyword>
</DOC>